论文部分内容阅读
目的观察Notch1和JAG1在乳腺癌中的表达及其与乳腺癌相关因素的关系,探讨Notch信号在人类乳腺癌中的作用。方法应用逆转录聚合酶链反应(RT-PCR)检测62例乳腺癌组织及22例癌旁正常乳腺组织中Notch1和JAG1的表达,对乳腺癌组织与癌旁正常乳腺组织进行表达率和表达强度标准化系数的统计学比较,并在不同的腋窝淋巴结转移情况间、不同的临床分期间进行Notch1表达强度标准化系数的统计学比较。结果乳腺癌组织Notch1的表达率和标准化系数分别为98.0%和0.91,均明显高于癌旁正常乳腺组织,乳腺癌组织中JAG1的表达率为15.0%,癌旁组织中无JAG1表达;伴腋窝淋巴结转移的病例Notch1标准化系数高于无腋窝淋巴结转移的病例;乳腺癌Ⅰ期病例Notch1标准化系数(0.66)低于Ⅱ期(1.20),Ⅱ期高于Ⅲ期(0.62),Ⅰ期与Ⅲ期差异无统计学意义。结论人类乳腺癌中存在Notch1和JAG1的异常高表达,提示Notch1的异常表达与活化人能与人类乳腺癌的形成有关,Notch1在人类乳腺癌不同发展阶段的作用可能不同。
Objective To observe the expression of Notch1 and JAG1 in breast cancer and its relationship with breast cancer related factors and to explore the role of Notch signaling in human breast cancer. Methods The expression of Notch1 and JAG1 in 62 cases of breast cancer tissues and 22 cases of adjacent normal breast tissues were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The expression and expression of Notch1 and JAG1 in breast cancer tissues and adjacent normal breast tissues Statistical comparison of standardized coefficients, and statistical comparison of Notch1 expression intensity standardized coefficients between different axillary lymph node metastases and clinical stages. Results The expression rate and normalization coefficient of Notch1 in breast cancer tissues were 98.0% and 0.91, respectively, which were significantly higher than those in adjacent normal breast tissues. The expression rate of JAG1 in breast cancer tissues was 15.0%, while there was no JAG1 expression in paracancerous tissues. The normalization rate of Notch1 in cases with lymph node metastasis was higher than that in cases without axillary lymph node metastasis. The standardized coefficient of Notch1 in stage Ⅰ breast cancer was lower than that in stage Ⅱ (1.20), stage Ⅱ was higher than stage Ⅲ (0.62) The difference was not statistically significant. Conclusion The abnormal expression of Notch1 and JAG1 in human breast cancer suggests that abnormal expression of Notch1 may be related to the formation of human breast cancer. The role of Notch1 in different stages of human breast cancer may be different.